How Analysts Feel About Aerie Pharmaceuticals Inc (NASDAQ:AERI) After Decrease in Sellers?

September 14, 2018 - By Rene Reddy

Investors sentiment increased to 1.22 in 2018 Q2. Its up 0.03, from 1.19 in 2018Q1. It improved, as 19 investors sold Aerie Pharmaceuticals, Inc. shares while 48 reduced holdings. 23 funds opened positions while 59 raised stakes. 39.97 million shares or 1.35% more from 39.43 million shares in 2018Q1 were reported.
Metropolitan Life holds 11,576 shares or 0% of its portfolio. California State Teachers Retirement Systems reported 0.01% stake. Moreover, Pnc Grp has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Aperio Gp Ltd invested in 0% or 5,273 shares. Royal Bankshares Of Canada has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Mufg Americas holds 0% or 304 shares. Jennison Assoc Ltd accumulated 1.31 million shares or 0.09% of the stock. State Board Of Administration Of Florida Retirement System has 18,371 shares. Missouri-based Atwood & Palmer has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Loomis Sayles & Limited Partnership owns 0.04% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 303,344 shares. Morgan Stanley has 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 467,300 shares. Waddell And Reed Financial Inc, a Kansas-based fund reported 460,717 shares. Barclays Public Ltd Company has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Putnam Investments Lc holds 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 16,517 shares. Credit Suisse Ag has invested 0.02% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Since May 21, 2018, it had 2 insider purchases, and 8 sales for $26.72 million activity. $9.34M worth of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) was sold by ANIDO VICENTE JR on Wednesday, June 6. The insider Cagle Gerald D. bought 1,000 shares worth $49,450. MITRO THOMAS A also sold $11.45 million worth of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Monday, August 27.

The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) registered a decrease of 5.16% in short interest. AERI’s total short interest was 4.15M shares in September as published by FINRA. Its down 5.16% from 4.37 million shares, reported previously. With 470,800 shares average volume, it will take short sellers 9 days to cover their AERI’s short positions. The short interest to Aerie Pharmaceuticals Inc’s float is 13.04%.

The stock increased 0.13% or $0.075 during the last trading session, reaching $59.525. About 42,496 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 4.95% since September 14, 2017 and is uptrending. It has underperformed by 10.67% the S&P500.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.69 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 4 analysts covering Aerie Pharma (NASDAQ:AERI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharma has $8700 highest and $7700 lowest target. $82’s average target is 37.76% above currents $59.525 stock price. Aerie Pharma had 5 analyst reports since March 29, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Tuesday, May 8. Cantor Fitzgerald has “Buy” rating and $8600 target. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Mizuho on Wednesday, May 9. As per Tuesday, September 11, the company rating was maintained by Stifel Nicolaus. The firm has “Buy” rating given on Wednesday, May 9 by H.C. Wainwright. The firm has “Buy” rating given on Thursday, March 29 by Mizuho.

More important recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on September 14, 2018, also Nasdaq.com published article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris …”, Seekingalpha.com published: “FDA OKs Sun Pharma’s Xelpros for lowering IOP in glaucoma patients” on September 14, 2018. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) was released by: Bizjournals.com and their article: “EXCLUSIVE: Aerie’s drive to change the world of eye care” with publication date: August 23, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.